Journal article 41 views
Barriers and strategies to medication adherence amongst people with multiple sclerosis and cognitive problems
Sarah Thomason 
,
Nima Moghaddam,
Nikos Evangelou,
Rod Middleton ,
Roshan das Nair
,
Nima Moghaddam,
Nikos Evangelou,
Rod Middleton ,
Roshan das Nair
Multiple Sclerosis and Related Disorders, Volume: 88, Start page: 105727
Swansea University Author:
Rod Middleton
Full text not available from this repository: check for access using links below.
DOI (Published version): 10.1016/j.msard.2024.105727
Abstract
BackgroundAdherence to disease-modifying treatment (DMT) amongst people with multiple sclerosis (MS) varies greatly. Although research often identifies 'forgetting' as a reason for poor adherence, few studies have considered how cognitive problems impact adherence.ObjectivesTo investigate...
| Published in: | Multiple Sclerosis and Related Disorders |
|---|---|
| ISSN: | 2211-0348 |
| Published: |
Elsevier BV
2024
|
| Online Access: |
Check full text
|
| URI: | https://cronfa.swan.ac.uk/Record/cronfa68037 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract: |
BackgroundAdherence to disease-modifying treatment (DMT) amongst people with multiple sclerosis (MS) varies greatly. Although research often identifies 'forgetting' as a reason for poor adherence, few studies have considered how cognitive problems impact adherence.ObjectivesTo investigate prevalence of and barriers to adherence, including for people with MS-related cognitive problems, and to identify adherence-related strategies.MethodsRecruited via the UK MS Register and MS Society groups, participants completed a Medication Adherence Questionnaire and the Perceived Deficits Questionnaire. A subset were interviewed.Results: Of 257 participants, 94 % reported being adherent, although 59 % missed ≥1 dose, and 25 % reported cognitive problems. Adherence was lower amongst those with cognitive problems, who experienced more barriers: memory problems; negative feelings about taking medication; and not wanting medication to interfere with activities. Such barriers, along with mood, cognition, and method of DMT administration, explained 17 % of variance in adherence, with intravenous treatment a significant predictor. Cognitive problems explained a unique proportion of variance; however, was non-significant when anxiety was factored in. Interviews highlighted how anxiety about side-effects and injections, and difficulties accepting the diagnosis, hindered use of reminders.ConclusionInterventions for cognition and mood problems, minimising treatment burden and supporting adjustment to diagnosis, may improve adherence. |
|---|---|
| College: |
Faculty of Medicine, Health and Life Sciences |
| Funders: |
MS Society |
| Start Page: |
105727 |